Veradigm Inc. (MDRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Veradigm: You Can't Fall Off The Floor
Veradigm trades near 20-year lows after accounting issues, delisting, and management upheaval, but its core business remains fundamentally sound. New management is focused on becoming current with SEC filings, operational efficiency, and reigniting growth, with relisting on Nasdaq by the end of 2026 as a key catalyst. Approximately 80% of MDRX revenue is recurring, with a sticky customer base and high switching costs; recent cost cuts and product rationalization aim to boost profitability.
Veradigm Inc. (MDRX) Discusses Strategic Reset, Product Portfolio Decisions and Growth Initiatives Transcript
Veradigm Inc. (MDRX) Discusses Strategic Reset, Product Portfolio Decisions and Growth Initiatives Transcript
Veradigm Inc. (MDRX) Investor Update Call Transcript
Veradigm Inc. (OTC:MDRX) Investor Update Call March 19, 2025 8:00 AM ET Company Participants Jenny Gelinas - VP, IR Tom Langan - Interim CEO Lee Westerfield - Interim CFO Conference Call Participants Charles Rhyee - TD Cowen Jeff Garro - Stephens George Hill - Deutsche Bank Operator Greetings, and welcome to the Veradigm Investor Update Call. At this time, all participants are in a listen-only mode.
Veradigm agrees to board refreshment in settlement with Kent Lake Capital
Veradigm will add four new directors to its board in an agreement with investor Kent Lake Capital, the healthcare technology company said on Thursday just weeks after concluding a strategic review.
Veradigm And The 2025 M&A Boom
America Unshackled. Early wins for the post-hipster antitrust era. Releasing the market from punitive regulators could be the biggest W.
